期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

唑来膦酸治疗恶性肿瘤骨转移66例分析 被引量：5

An Analysis on Zoledronic Acid in Management of Bone Metastasis due to 66 Cases with Malignancy
下载PDF
导出
摘要 [目的]观察唑来膦酸治疗各种恶性肿瘤所致骨转移的临床疗效及毒副作用。[方法]66例晚期恶性肿瘤骨转移患者接受唑来膦酸4mg加入0.9%生理盐水250ml中静脉滴注1h,每月1次。[结果]疼痛缓解总有效率为66.7%(44/66),对活动能力改善的有效率为66.7%(12/18);85.7%(36/42)的患者吗啡用量减少。治疗前血清钙2.39±0.43mmol/L,血清碱性磷酸酶(AKP)246.17±197.81U/L,治疗后则分别为2.06±0.18mmol/L(P=0.001)和213.68±171.55U/L(P=0.037)。毒副反应主要为发热、流感样症状及轻度恶心呕吐。[结论]唑来膦酸不仅能有效缓解疼痛,恢复活动能力,提高患者的生活质量;而且能显著降低血清钙、AKP浓度。
作者 李志革 周达 王惠临
机构地区 广西医科大学肿瘤医院
出处 《中国肿瘤》 CAS 2007年第11期959-960,共2页 China Cancer
关键词 恶性肿瘤 骨转移 双磷酸盐
分类号 R730.6 [医药卫生—肿瘤]
  • 相关文献

参考文献5

  • 1Langer CJ. Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer[J]. Clin Lung Cancer, 2005, 6(5):314-316.
  • 2Hillner BE,Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer[J]. J Clin Oncol, 2003, 21(21 ):4042-4057.
  • 3Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase Ⅱ trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy[J]. J Clin Oncol, 2006, 24(30):4895-4900.
  • 4Storto G,Klain M, Paone G, et al. Combined therapy of Sr- 89 and zoledronic acid in patients with painful bone metastases[J]. Bone, 2006, 39(1):35-41.
  • 5Cartenl G, Bordonaro R, Giotta F, et al. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial[J]. Oncologist, 2006, 11(7):841-848.

同被引文献31

  • 1孙辉,周均田,张燕军,陈振东,王秀问,刘基巍.注射用唑来膦酸治疗恶性肿瘤引起的溶骨性骨转移疼痛临床研究报告[J].中国肿瘤临床,2005,32(15):885-888. 被引量：15
  • 2Saad F, Olsson C, Schtdman CC. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care[J]. Eur Urol, 2004, 46(6) : 731-740.
  • 3Green JR. Bisphosphonates: preclinical review[J]. Oncologist, 2004, 9 Suppl 4: 3-13.
  • 4Costa L, Lipton A, Coleman RE. Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases[J]. Support Cancer Ther, 2006, 3(3): 143-153.
  • 5GralowJ, Tripathy D. Managing metastatic bone pain: the role of bisphosphonates [J]. J Pain Symptom Manage, 2007, 33(4): 462-472.
  • 6Polascik TJ, Mouraviev V. Zoledronic acid in the management of metastatic bone disease[J]. Ther Clin Risk Manag, 2008, 4(1): 261-268.
  • 7Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in paden- ts with bone metastases[J]. Nat Clin Pract Oncol, 2009, 6(3): 163-174.
  • 8Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatmem of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase Ⅲ, double-blind, placebo-controlled trial[J]. Gancer, 2004, 100(12): 2613-2621.
  • 9段蔚伯,余子豪,徐国镇等.肿瘤放射治疗学[M].第4版.北京:中国协和医科大学出版社,2008:1191-1194.
  • 10孙燕,石远凯.肿瘤放射内科手册[M].第5版.北京:人民卫生出版社,2007:920-921.

引证文献5

二级引证文献33

中国肿瘤
2007年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部